387,188 Shares in AngioDynamics, Inc. $ANGO Bought by Western Standard LLC

Key Points

• Western Standard LLC acquired 387,188 shares of AngioDynamics worth approximately $5.04 million, representing 0.94% of the company and 1.7% of the investor’s portfolio. Institutional investors collectively own 89.43% of ANGO.
• Analyst sentiment is mixed, with ratings ranging from Strong Buy to Sell; the consensus rating is Hold with a $19.50 price target. Canaccord Genuity and HC Wainwright recently raised their targets to $20 and $19, respectively.
• AngioDynamics beat quarterly expectations, reporting a loss of $0.07 per share versus the projected $0.11 loss and revenue of $86.61 million versus an $80.24 million estimate. Despite the beat, the company remains unprofitable, with an 11.48% negative net margin.

Western Standard LLC purchased a new stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 387,188 shares of the medical instruments supplier's stock, valued at approximately $5,037,000. AngioDynamics makes up approximately 1.7% of Western Standard LLC's portfolio, making the stock its 17th largest position. Western Standard LLC owned 0.94% of AngioDynamics at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ANGO. Goldman Sachs Group Inc. grew its holdings in AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier's stock worth $2,434,000 after acquiring an additional 22,658 shares in the last quarter. Jane Street Group LLC raised its stake in shares of AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier's stock valued at $439,000 after purchasing an additional 34,054 shares in the last quarter. Legal & General Group Plc raised its stake in shares of AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier's stock valued at $123,000 after purchasing an additional 9,098 shares in the last quarter. Rhumbline Advisers lifted its position in shares of AngioDynamics by 4.3% during the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier's stock worth $608,000 after purchasing an additional 2,510 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in shares of AngioDynamics by 15.8% during the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier's stock worth $960,000 after purchasing an additional 13,217 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ANGO has been the subject of several research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a report on Friday, July 17th. Zacks Research downgraded AngioDynamics from a "hold" rating to a "strong sell" rating in a report on Thursday, July 16th. Canaccord Genuity Group lifted their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Finally, HC Wainwright boosted their price target on AngioDynamics from $16.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $19.50.

AngioDynamics Stock Performance

AngioDynamics stock opened at $16.07 on Thursday. AngioDynamics, Inc. has a 1 year low of $8.74 and a 1 year high of $16.29. The firm's 50-day moving average is $13.81 and its 200-day moving average is $11.99. The company has a market cap of $664.17 million, a P/E ratio of -18.47 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. As a group, sell-side analysts predict that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the company's stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares of the company's stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.00% of the stock is currently owned by insiders.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source